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Abstract
Background: Mobilized-peripheral blood hematopoietic stem cells (HSCs) have been used for
transplantation, immunotherapy, and cardiovascular regenerative medicine. Agents used for HSC
mobilization include G-CSF and the CXCR4 inhibitor AMD3100 (plerixafor). The HSCs cells
mobilized by each agent may contain different subtypes and have different functions. To
characterize mobilized HSCs used for clinical applications, microRNA (miRNA) profiling and gene
expression profiling were used to compare AMD3100-mobilized CD133+ cells from 4 subjects,
AMD3100 plus G-CSF-mobilized CD133+ cells from 4 subjects and G-CSF-mobilized CD34+ cells
from 5 subjects. The HSCs were compared to peripheral blood leukocytes (PBLs) from 7 subjects.
Results: Hierarchical clustering of miRNAs separated HSCs from PBLs. miRNAs up-regulated in
all HSCs included hematopoiesis-associated miRNA; miR-126, miR-10a, miR-221 and miR-17-92
cluster. miRNAs up-regulated in PBLs included miR-142-3p, -218, -21, and -379. Hierarchical
clustering analysis of miRNA expression separated the AMD3100-mobilized CD133+ cells from G-
CSF-mobilized CD34+ cells. Gene expression analysis of the HSCs naturally segregated samples
according to mobilization and isolation protocol and cell differentiation status.
Conclusion: HSCs and PBLs have unique miRNA and gene expression profiles. miRNA and gene
expression microarrays maybe useful for assessing differences in HSCs.
Background
Hematopoietic stem cells (HSCs) have been used for
more than 35 years for transplantation therapy to treat
acute and chronic leukemia, lymphoma, marrow failure
and congenital immune deficiency. Advances in immuno-
therapy have lead to the use of HSCs to produce dendritic
cells (DCs) to enhance antigen presentation [1], to
enhance leukocyte recovery after immunosuppresive ther-
apy, and to mount cancer rejection by adoptive transfer of
tumor infiltrating lymphocytes (TIL) [2]. HSCs have also
been used to treat patients with ischemic cardiac disease
to improve revascularization and cardiac function follow-
ing acute myocardial ischemia [3,4]. However, due to the
diversity of stem cell sources, mobilization methods
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employed, purity of cells, and the content of cell subsets,
there are many different types of HSCs and those that are
most beneficial for one application may not be best for
another.
HSCs can be obtained from several different sources
including bone marrow, mobilized peripheral blood, and
umbilical cord blood. For transplantation, traditionally,
HSCs were obtained from the bone marrow. However,
umbilical cord blood has been found to be especially rich
in HSCs [5] and HSCs have been found in the peripheral
blood and their level in the circulation increases several-
fold after G-CSF administion [6,7]. For HSC transplanta-
tion all three types of HSCs are used, but for most other
applications mobilized peripheral blood HSCs are most
commonly used.
The diversity of HSCs used for clinical therapies has also
increased due to the development of new HSC mobilizing
agents. For many years granulocyte colony-stimulating
factor (G-CSF) has been the standard agent to increase the
level of circulating HSCs. The administration of G-CSF
daily for 4 to 6 days results in a 10- to 30-fold increase in
the number of circulating HSCs [8,9] and G-CSF-mobi-
lized HSCs collected by apheresis have been used for
transplantation, immune therapy and the treatment of
cardiac ischemia. Another HSC mobilizing agent,
AMD3100, has been used with G-CSF to mobilize stem
cells for autologous transplants [10] and is currently being
evaluated as a single agent to mobilize HSCs for alloge-
neic donor transplants [11,12].
The mechanisms by which AMD3100 and G-CSF alter
HSC trafficking and mobilization are different suggesting
that HSCs with different intrinsic properties maybe be
mobilized by these agents. AMD3100, as a CXCR4 antag-
onist, mobilizes HSCs within 6 hours by disrupting the
engagement of stem cell surface CXCR4 with its ligand
SDF-1 (CXCL12) which is expressed on marrow osteob-
lasts [10,13-20]. In contrast G-CSF mobilizes stem cells
indirectly by down regulating the expression of SDF-1 on
marrow osteoblasts and by releasing neutrophil and
monocyte proteolytic enzymes including neutrophil
elastase, cathepsin G, and maxtrix metalloproteinase-9
which in turn degrade important HSC trafficking and
adhesion molecules c-kit, VCAM-1, CXCR4, and SDF-1
[21]. In animal studies AMD3100 mobilizes a CD34+ cell
population with a greater long-term marrow repopulating
capacity than G-CSF [12,22,23], possibly due to differ-
ences in mechanisms of mobilization.
Although commonly accepted HSC specific surface mark-
ers have been used for HSC characterization and purifica-
tion, differences in the specificities of monoclonal
antibodies used to isolate HSCs have contributed to diver-
sity in HSC clinical products. Antibodies specific for
CD34 have been the standard agent for the isolation of
HSCs. In addition, anti-CD133 has also been used [24-
27]. Approximately 75% of G-CSF mobilized peripheral
blood stem cells (PBSCs) express CD34 as well as CD133,
but small populations express one or the other [28].
MicroRNAs (miRNA) are short, 20–22 nucleotide long,
RNA molecules which negatively regulate protein transla-
tion in a variety of biological processes, including devel-
opmental timing, signal transduction, tissue
differentiation and stem cell renewal and differentiation.
Some miRNAs are specifically expressed in stem cells and
control stem cell self-renewal and differentiation by nega-
tively regulating the expression of certain key genes in
stem cells.
To determine if miRNA and gene expression profiling
would be beneficial in distinguishing different types of
HSCs, we compared CD133+ cells isolated from
AMD3100- and AMD3100 plus G-CSF-mobilized PBSC
concentrates with CD34+ cells isolated from G-CSF-mobi-
lized PBSC concentrates. We applied miRNA profiling and
gene expression profiling analysis to assess these three dif-
ferent types of progenitor cell populations using periph-
eral blood T cells, B cells, monocytes and NK cells as a
reference. We hypothesized that miRNA and gene expres-
sion analysis would be useful for characterizing HSCs.
Global gene and miRNA expression profiling was used to
compare HSCs and peripheral blood leukocytes. T cells, B
cells, monocytes and NK cells isolated from peripheral
blood mononuclear cells (PBMCs) were compared to the
HSCs.
Methods
Hematopoietic progenitor cell isolation
AMD3100 and AMD3100 plus G-CSF stem cell mobilization, 
collections and isolation
For the mobilization of cells with AMD3100 alone, one
dose of AMD3100 (Plerixafor, Genzyme Corporation,
Cambridge, MA) (240 μg/kg) was given subcutaneously
and PBSC concentrate was collected by leukapheresis
(CS3000, Baxter Healthcare Corp., Fenwal Division, Deer-
field, IL) six hours later. For AMD3100 plus G-CSF-mobi-
lization G-CSF (10 μg/kg) (Filgrastim, Amgen, Thousand
Oaks, CA) was given subcutaneously to healthy subjects
daily for four days and on the fifth day in addition to G-
CSF, AMD3100 (240 μg/kg) was given subcutaneously. A
mobilized PBSC concentrate was collected by leukapher-
esis (CS3000, Baxter Healthcare Corp.) on day 5 twelve
hours after the administration of AMD3100 and 2 hours
after the last dose of G-CSF. CD133+ cells were isolated
from the PBSC concentrates by positive selection with
anti-CD133 and magnetic microparticles (CliniMacs,
Miltenyi Biotec, Bergisch Gladbach, Germany) and theJournal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
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isolated cells were cryopreserved. The proportion of iso-
lated cells that expressed CD133 ranged from 88% to
98%.
G-CSF stem cell mobilization, collection, and isolation
Healthy subjects were given G-CSF (10 μg/kg) (Filgrastim,
Amgen Thousand Oaks, CA) subcutaneously daily for 5
days. A mobilized PBSC concentrate was collected by leu-
kapheresis (CS3000, Baxter Healthcare Corp) on the fifth
day and cryopreserved in 5% DMSO and 6% pentastarch
using a controlled rate freezer and stored in liquid nitro-
gen. The PBSC concentrate was thawed and CD34+ cells
were isolated by immunoaffinity chromatography with
CD34 monoclonal antibody and magnetic beads (Isolex,
Baxter Healthcare). The proportion of isolated cells that
expressed CD34 ranged from 87% to 98%.
Non-mobilized PBMC collection and sample preparation
A non-mobilized PBMC concentrate was collected from 7
healthy subjects by apheresis (CS3000) at the Department
of Transfusion Medicine (DTM), Clinical Center (CC),
National Institutes of Health (NIH). All subjects signed an
informed consent approved by the NIH. Mononuclear
leukocytes were separated from contaminating granulo-
cytes and red blood cells by Ficoll gradient separation, cry-
opreserved and stored in liquid nitrogen. T cells, B cells,
NK cells and monocytes were isolated by positive selec-
tion by using anti-CD3, anti-CD19, anti-CD56 and anti-
CD14 magnetic beads, respectively (AutoMACS, Miltenyi
Biotec) (purity ≥ 90%).
RNA preparation, amplification and labeling
Total RNA was isolated from each sample by using TRI-
ZOL reagent (Invitrogen, Carlsbad, CA).
cDNA expression array
Total RNA (3 μg) was amplified from 0.5 × 106 to 107 cells
into anti-sense RNA (aRNA), also, total RNA from PBMCs
pooled from six normal donors was extracted and ampli-
fied into aRNA to serve as the constant reference [29] Test
and reference RNAs were labeled with Cy5 (red) and Cy3
(green) dyes, respectively, and co-hybridized to the cus-
tom-made 17.5 K cDNA (UniGene cluster) microarrays
which were printed in the Immunogenetics Section of
DTM with a configuration of 32 × 24 × 23 [30]. Clones
used for printing included a combination of the Research
Genetics RG_HsKG_031901 8 k clone set and 9,000
clones selected from the RG_Hs_seq_ver_070700 40 k
clone set. The 17,500 spots included 12,072 uniquely-
named genes, 875 duplicated genes and about 4,000
expression sequence tags. The complete list of genes
included in the Hs-CCDTV-17.5k-1px printing is available
at the web site http://nciarray.nci.nih.gov/gal_files/Hs-
CCDTM17.5k-2px.gal.
MicroRNA array
A miRNA probe set was designed using mature antisense
miRNA sequences (Sanger data base, version 8.1) consist-
ing of 736 human, mouse, rat and virus plus two control
probes. The probes were 5' amine modified and printed in
duplicate in the Immunogenetics Section of the DTM on
CodeLink activated slides (General Electric, GE Health,
NJ, USA) via covalent bonding.Small RNA was enriched
from 10 ug total RNA by flashPAGE (Pre-cast Gel, Type A)
(Ambion, Austin, TX, USA) and purified using flashPAGE
reaction clean-up kit (Ambion, Austin, TX, USA) accord-
ing to manufacture's instruction. The same procedures
were applied to obtain small RNA from the Epstein-Barr
virus (EBV)-transformed lymphoblastoid cell lines that
was used as the reference for the miRNA expression array
assay. Fragmented small RNA were 3'-end tailed with
amine-modified nucleotides and chemically coupled to
CyDye fluors (Amersham Biosciences, piscatway, NJ,
USA), the test sample with Cy5 and the reference with
Cy3, using the mirVana miRNA Labeling Kit (Ambion)
following the manufacturer recommended protocol. After
labeling, the samples and the reference were co-hybrid-
ized to the miRNA array at room temperature over night.
Both the processed cDNA and the miRNA array slides
were scanned by GenePix scanner Pro 4.0 (Axon, Sunny-
vale, CA, USA).
Data and statistical analyses
The raw microarray data set was filtered according to a
standard procedure to exclude spots with minimum
intensity that was arbitrarily set to an intensity parameter
of ≥ 300 for cDNA expression data and ≥ 100 for the
miRNA microarray data in both fluorescence channels. If
the fluorescence intensity of one channel was below the
cut-off while the other was above, the lower channel
intensity was overridden. Spots with diameters < 25 μm
for cDNA expression array and < 10 μm for miRNA micro-
arry and flagged spots were also excluded from the analy-
ses. Then, the filtered data were normalized using Lowess
Smoother and retrieved by the BRB ArrayTool http://
linus.nci.nih.gov/BRB-ArrayTools.html developed at the
National Cancer Institute (NCI), Biometric Research
Branch, Division of Cancer Treatment and Diagnosis.
Hierarchical cluster analysis and TreeView software [31]
were used for visualization [32]. All of the predictions of
miRNA gene targets were made using BRB ArrayTool
microRNA targets http://linus.nci.nih.gov/BRB-Array
Tools.html developed at the NCI, Biometric Research
Branch, Division of Cancer Treatment and Diagnosis.
Results
Peripheral blood leukocytes and hematopoietic progenitor 
cells
PBMC concentrates were collected by apheresis from 7
healthy subjects. B cells, T cells, NK cells, and monocytesJournal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
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were isolated from each PBMC concentrate. 92% to 98%
of the isolated B cells expressed CD21, 95% to 98% of T
cells expressed CD3, 90% to 97% of NK cells expressed
CD56 and 92% to 98% of monocytes expressed CD14.
Mobilized peripheral blood HSCs were collected from 13
healthy subjects: 5 were given G-CSF and their HSCs iso-
lated with anti-CD34 while 4 were given AMD3100 alone
and 4 were given AMD3100 plus G-CSF and their HSCs
isolated with anti-CD133. In the four donors given
AMD3100 plus G-CSF the concentration of circulating
CD34+ cells increased from 62 ± 45 × 106/L prior to the
administration of AMD3100 to 215 ± 117 × 106/L twelve
hours after AMD3100 was given, suggesting that
AMD3100 was responsible for mobilizing a substantial
portion of the circulating CD34+ cells. In the four donors
given AMD3100 the CD34+ cell counts increased from a
baseline level of 3 ± 4 × 106/L to 23 ± 4 × 106/L 6 hours
after the administration of AMD3100.
Comparison of miRNA expression among hematopoietic 
progenitor cells and peripheral blood leukocytes
Among the 13 HSC samples and the 28 peripheral blood
leukocyte (PBL) samples analyzed ≥ 80% of the samples
expressed 148 miRNAs of the 457 human miRNA in our
chip. Unsupervised hierarchical clustering analysis based
on the 148 miRNAs revealed 3 distinct groups: the exclu-
sively HSC cluster; the T (n = 5) and NK cell (n = 3) cluster;
and the B cell and monocyte dominant cluster which con-
MicroRNA (miRNA) expression profiles of hematopoietic stem cells (HSCs) and peripheral blood leukocytes (PBLs) Figure 1
MicroRNA (miRNA) expression profiles of hematopoietic stem cells (HSCs) and peripheral blood leukocytes 
(PBLs). RNA was isolated from T cells, B cells, monocytes and NK cells from 7 subjects, G-CSF-mobilized CD34+ cells from 
5 subjects, AMD3100 (A)-mobilized CD133+ cells from 4 subjects, and AMD3100 plus G-CSF (A+G)-mobilized CD133+ cells 
from 4 subjects and miRNA expression was analyzed using an expression array with 457 human miRNAs. A) Unsupervised 
hierarchical clustering of Eisen was used to analyze the 148 miRNAs that remained after filtering (miRNA expressed in ≥ 80% 
of samples). B) Signature miRNAs whose expression was markedly up-regulated in HSCs or PBLs.
A
Hematopoietic progenitor cells
Mature cells
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tained a mixture of B cells (n = 7), monocytes (n = 7), T
cells (n = 2) and NK cells (n = 4) (Figure 1A). Within the
HSC group the 4 AMD3100-mobilized and the 4
AMD3100 plus G-CSF-mobilized CD133+ cells clustered
together, but separate from the G-CSF-mobilized CD34+
cells.
The make-up of the miRNAs that separated HSCs and
PBLs differed markedly. Eight signature miRNAs demon-
strated increased expression and 3 miRNAs decreased
expression in HSCs compared to PBLs (Figure 1B). The 8
signature HSC miRNAs whose expression was increased
included miR-19a, -19b, -20a, and 20b, which are part of
the polycistronic cancer-associated miR-17-92 cluster. The
3 signature miRNAs whose expression was greatest in the
PBL samples were miR-142-3p, miR-21, and miR-142-5p.
Both probes for miR-20b were up-regulated in HSCs and
both for miR-142-3p were up-regulated in PBLs.
To identify the entire set of miRNAs whose expression dif-
fered between HSCs and PBLs, the expression of miRNAs
by all 13 HSC samples was compared with those by all 28
PBL samples (t-test, p < 0.005). The expression of 35 miR-
NAs differed between the two types of cells: the expression
of 13 miRNAs were increased in HSCs and 22 miRNAs
were increased in PBLs (Table 1). The expression of two
miRNAs, miR-126 and miR-10a, were markedly increased
in HSCs. Both miR-126 and miR-10a and 7 others, miR-
19a, -19b, -17-5p, 20b, -93, -130a and -221, have been
previously reported to be expressed by HSCs [33-35].
Among the 13 miRNAs whose expression was increased in
HSCs were 3 miRNAs belonging to the cancer-associated
miR-17-92 cluster; miR-19a, 19b, and -17-5p. When the
expression of all the miRNAs in the miR-17-92 cluster (n
= 7) were compared between HSCs and PBLs, 5 of the 7
were increased in HSCs (Table 2). Regulated by the onco-
gene cMyc, the miR-17-92 cluster targets large numbers of
genes. Consistent with this notion, the expression of cMyc
gene was increased 3.3-fold in HSCs based on our gene
expression analysis. The expression of 3 miRNAs in a sec-
ond cancer-associated miR-106-303 cluster were also
increased in HSCs (Table 2). In contrast, expression of two
cancer suppressing miRNAs, miR-15a and miR-16, were
decreased in HSCs.
Among the 148 miRNAs 47 were differentially expressed
between AMD3100-mobilized CD133+ cells and the G-
CSF-mobilized CD34+ cells (t-tests, p < 0.005). The
expression of 17 was increased in the AMD3100 group
and 30 were increased in the G-CSF group (data not
shown).
The expression of 4 miRNAs were markedly increased in
PBL: miR-142-3p, miR-218, miR-21, and miR-379. In
Table 1: MicroRNAs (miRs) whose expression differed among 13 hematopoietic stem cell 
miRs whose expression was
 increased in HSCs
Fold-increase miRs whose expression
 was increased in PBLs
Fold-increase
hsa-miR-126 14.43 hsa-miR-142-3p 15.66
hsa-miR-10a 13.46 hsa-miR-218 11.07
hsa-miR-19a 3.89 hsa-miR-21 8.46
hsa-miR-19b 3.11 hsa-miR-379 7.63
hsa-mir-595 2.98 hsa-miR-381 4.61
hsa-miR-146a 2.72 hsa-miR-29b 3.83
hsa-miR-93 2.56 hsa-miR-26b 3.54
hsa-miR-221 2.38 hsa-miR-30c 3.12
hsa-miR-20b 2.35 hsa-miR-142-5p 2.51
hsa-miR-130a 2.25 hsa-miR-29a 2.49
hsa-miR-34a 2.12 hsa-let-7g 2.49
hsa-miR-363 1.92 hsa-let-7i 2.42
hsa-miR-17-5p 1.89 hsa-miR-191 2.3
hsa-miR-30b 2.03
hsa-let-7b 1.88
hsa-miR-26a 1.85
hsa-miR-16 1.78
hsa-let-7c 1.75
hsa-miR-30a-5p 1.73
hsa-miR-373 1.62
hsa-mir-594 1.6
hsa-mir-610 1.34
(HSC) and 28 peripheral blood leukocyte (PBL) samples*
* The expression of miRs between the two groups were compared with t-tests (p < 0.005)Journal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
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addition to these 4 miRNAs, expression of miR-16 which
belongs to the leukemia associated cluster miR-15a-16
was also increased.
To identify miRNAs uniquely expressed among PBLs, 5-
way ANOVA was performed to compare the expression of
the 148 miRNAs among T cell, B cell, monocyte, NK cell
and the HSC samples. T cells were characterized by
increased expression of miR-146a, -146b, -29a, and -29b
and B cells were characterized by the increased expression
of miR-29a -29b, and -29c (Table 3). The expression of
several miRNAs including miR-223 and miR-21 were
increased in monocytes, but none were increased NK cells
(Table 3).
cDNA expression profiling
Analysis of miRNA expression revealed that HSCs and
PBLs had unique miRNA expression profiles. To investi-
gate this further, gene expression profiles were also com-
pared using cDNA expression microarrays which
contained 17,088 genes. Unsupervised hierarchical clus-
tering of the 11,023 genes that were expressed in ≥ 80% of
the samples separated the HPC and PBL samples into two
distinct groups (Figure 2). All of the HSC samples clus-
tered separately from mature PBL subsets. The AMD3100-
mobilized CD133+ cells and the AMD3100 plus G-CSF-
mobilized CD133+ cells clustered together and again were
considered as one group, the AMD3100 group. The two
different types of HSCs, AMD3100-mobilized CD133+
cells and G-CSF-mobilized CD34+ cells clustered sepa-
rately (Figure 2). In addition, T cell, B cell, monocyte, and
NK cell samples clustered into separate groups (Figure 2).
A comparison of genes expressed by HSCs and PBLs
revealed that 5,392 genes were differentially expressed
among the two types of cells (t-tests, p < 0.001). The 30
genes whose expression increased the greatest in HSCs
included several transcription factors and oncogenes such
as GATA2 and N-myc, while the 30 genes whose expres-
sion was increased the most in PBLs were enriched for
genes known to be expressed by circulating leukocytes
such as Fc-γ receptor III (CD16), integrin α M subunit and
IL-10 receptor α (Table 4).
Discussion
In this study we discovered that miRNA expressed by HSC
differed from those expressed by PBLs. We also found that
miRNA profiling and cDNA expression analysis are poten-
tially useful tools for the analysis of clinical HSCs derived
by different mobilization and isolation methods which
may yield functionally diverse products.
Among the 13 miRNAs increased in HSCs miR-10a, -17-
5p, -19a, -19b, -20b, -93, -126, -130a, and -221; have pre-
viously been found to be expressed by HSCs [33-36]. miR-
126 and miR-10a have been found to be down-regulated
in erythrocyte and megakaryocyte precursors [33,36].
miR-221 has previously been shown to be important in
erythropoiesis; the expression of miR-221 and -222
inhibit erythropoiesis [37]. The expression of miR-221
has been reported to be down regulated in CD34+ cells
during erythropoesis [33,37]. The expression of miR-221
is also increased in papillary thyroid carincomas [38] and
is involved with the pathogenesis of hepatocelluar carin-
coma [39] and prostate cancer [40].
Polycistronically transcribed miRNA clusters, so called
onco-miR clusters, were also highly expressed by HSCs
compared to PBLs. These findings are consistent with the
theory that stem cells are important in cancer. The miR-
17-92 cluster has been reported to be up-regulated in dif-
fuse large B cell lymphoma (DLBCL), lung, breast, pros-
tate, and colon cancer [41-43]. Venurini and colleagues
found that the miR-17-92 cluster was up-regulated in
CD34+ cells from healthy subjects and those with early-
Table 2: Cancer-associated microRNAs (miRNAs) whose 
expression was up- and down-regulated in hematopoietic stem 
cells (HSCs)
Cluster miR-17-92
miRNA Fold-increase in HSCs P
17-p5 1.89 0.004
17-p3 NC NS
18a 1.31 0.018
19a 3.89 4 × 10-7
20a 1.55 0.015
19b-1 3.1 1.3 × 10-6
92-1 NC NS
Cluster miR-106-363
miRNA Fold-increase in HSCs P
106a 1.55 0.016
18b NC NS
20b 2.34 2.9 × 10-05
19b-2 3.1 1.3 × 10-06
92-2 NC NS
363 NC NS
Cluster miR-15-16
miRNA Fold-decrease in HSCs P
15a 3.33 0.007466
16 1.78 9.93 × 10-4
NC = no change
NS = not significantJournal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
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chronic phase chronic myelogenous leukemia, but was
not up-regulated in CD34+ cells from subjects with CML
blast crisis [44]. In addition, 3 of 6 members of the cancer-
associated miR-106-363 cluster were also up-regulated in
HSCs. Elevated expression of this cluster has been found
in T cell leukemia [45] and T cell lymphoma [46].
miR-21 was increased in PBLs. miR-21 has also been
found to be increased in chronic lymphocytic leukemia
[47], B cell lymphomas [48], breast cancer [49], pancreatic
cancer [50], head and neck cancer cell lines [51]. In addi-
tion, the expression of miR-16 was greater in PBLs, espe-
cially in monocytes, than HSCs. miR-15 and miR-16 are
cancer-associated miRNA that are down-regulated in B-
cell chronic lymphocyte leukemia [52,53] and pituitary
adenomas [54] but upregulated in acute promyelocytic
leukemia [55]. We also found that T cells were character-
ized by the upregulation of miR-29a and -29b and B cells
by miR-29a, -29b, and -29c. These miRNA are down-regu-
lated in aggressive B cell lymphoma [56].
At the transcription level we found that the expression of
a number of oncogenes and genes related to transcription
was greater in HSCs than in PBLs. The expression of
GATA2, a transcription factor important in hematopoietic
stem cell and endothelial cell differentiation [57,58] was
137-fold greater in HSCs and that of N-myc was 97-fold
greater. Computational gene target prediction http://
www.targetscan.org/ indicates that GATA2 is targeted by
miR-27a whose expression was 2-fold less in HSCs than
PBLs (p = 0.0069).
An interesting finding of this study resides in the differ-
ences in both miRNA and gene expression found between
G-CSF-mobilized CD34+ cells and AMD3100-mobilized
CD133+ cells. While both miRNA expression profiling
and DNA expression profiling differentiated the two dif-
ferent types of HSCs, these two populations were
obtained using different HSC mobilization and isolation
procedures. It is not certain if the differences in the two
stem cell types were due to the different mobilizing agents
Table 3: MicoRNAs (miRNAs) characteristic of each type of peripheral blood leukocyte*
T cells NK cells
Increased FC Decreased FC Increased FC Decreased FC
miR-146b 4.05 miR-223 16.8 None NA miR-19a 3.54
miR-29b 3.86 miR-181b 2.41 miR-19b 3.06
miR-146a 3.45 miR-93 2.32 miR-92 1.85
miR-29a 3.38 miR-20b 2.19
miR-17-5p 2.01
miR-20a 1.88
miR-106a 1.86
Monocytes B cells
Increased FC Decreased FC Increased FC Decreased FC
miR-223 21.0 miR-146b 5.85 miR-29b 4.53 miR-22 7.62
miR-21 10.1 miR-146a 5.71 miR-29a 3.66 miR-23a 6.15
miR-424 5.74 miR-29c 2.92 miR-29c 3.05 miR-24 5.87
miR-365 3.28 miR-146b 3.33
miR-191 3.28 miR-27a 3.29
miR-103 3.19 miR-23b 2.42
miR-23a 3.1
miR-27a 2.85
miR-15a 2.77
miR-374 2.74
miR-107 2.58
miR-106b 2.33
miR-16 2.1
miR-422b 2.01
miR-23b 1.78
miR-185 1.62
*The groups of cells were compared using F-tests (p < 0.005)
FC = fold changeJournal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
Page 8 of 12
(page number not for citation purposes)
or isolation antibodies. We suspect that both the mobiliz-
ing agents and antibodies contributed to the differences.
In addition, the G-CSF-mobilized CD34+ cells underwent
an additional freeze-thaw cycle. This was not expected to
affect the HSCs, but we can not exclude this possibility.
Further studies are needed which compare HSCs mobi-
lized with AMD3100 alone and with G-CSF alone and
with both types of stem cells isolated with the same mon-
oclonal antibody. Since both CD34 and CD133 are being
used to isolate stem cells for clinical applications, HSCs
mobilized with one agent and isolated with each antibody
should also be compared.
When considering new or different mobilization or isola-
tion protocols, changes in both the quantity and quality
of HSCs should be considered. The quantitation of
CD34+ cells has been the gold standard for assessing the
potency of HSCs for clinical therapies. When comparing
HSCs mobilized with G-CSF from different subjects, dif-
ferent G-CSF mobilization protocols, or different HSC
collection protocols, measuring CD34+ cells is a good
indicator of the potency of the HSCs. However, if stem
cells mobilized with G-CSF are to be compared with those
mobilized with AMD3100 or AMD3100 plus G-CSF,
measuring only CD34+ or CD133+ cells may not com-
pletely reflect the differences among these types of cells.
Gene expression profiles of hematopoietic stem cells (HSCs) and peripheral blood leukocytes (PBLs) Figure 2
Gene expression profiles of hematopoietic stem cells (HSCs) and peripheral blood leukocytes (PBLs). cDNA 
was isolated from T cells, B cells, monocytes and NK cells from 7 subjects, G-CSF (G)-mobilized CD34+ cells from 5 subjects, 
AMD3100 (A)-mobilized CD133+ cells from 4 subjects and AMD3100 plus G-CSF (A+G)-mobilized CD133+ cells from 4 sub-
jects. cDNA expression was analyzed using an expression microarray with 17,500 cDNA. Unsupervised hierarchical clustering 
of Eisen was used to analyze the 11,023 genes that remained after filtering (cDNA expressed in ≥ 80% of samples).Journal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
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Table 4: Genes differentially expressed between hematopoietic stem cells (HSCs) and peripheral blood leukocytes (PBLs)
Expression Increased in HSCs Expression Increased in PBLs
Gene Symbol Description Fold 
Change
Gene 
Symbol
Description Fold Change
GATA2 GATA-binding protein 2 237.82 CARD14 Caspase recruitment domain protein 14 25.59
MYCN N-myc 97.75 LTBR Lymphotoxin-Beta receptor precursor = 
Tumor necrosis factor receptor 2 related 
protein = Tumor necrosis factor C 
receptor
18.83
CRHBP CRF-BP = corticotropin-releasing factor 
binding protein
65.52 GPR65 TDAG8 = putative G protein-coupled 
receptor induced during activation-
induced apoptosis of T cells = G protein-
coupled receptor 65
18.33
FHL1 Four and a half LIM domains 1 58.2 FCGR3A CD16 = Fcgamma receptor IIIa 18.15
ERG V-ets erythroblastosis virus E26 oncogene 
homolog (avian)
43.57 ITGAM Integrin, alpha M 
(complement component 3 receptor 3 
subunit)
16.96
NPR3 Natriuretic peptide receptor C/guanylate 
cyclase C 
(atrionatriuretic peptide receptor C)
42.04 SGSH N-sulfoglucosamine sulfohydrolase 
(sulfamidase)
16.64
SCHIP1 Schwannomin interacting protein 1 41.77 ITGB7 Integrin, beta 7 16.39
MSRB3 Methionine sulfoxide reductase B3 35.29 GNLY Granulysin 15.21
MYB V-myb myeloblastosis viral oncogene 
homolog (avian)
32.99 ALOX5AP Arachidonate 5-lipoxygenase-activating 
protein
15.11
DEPDC6 DEP domain containing 6 28.85 CD48 CD48 = BLAST-1 14.81
EPDR1 Ependymin related protein 1 (zebrafish) 27.88 IL10RA Interleukin 10 receptor, alpha 13.71
TRH Thyrotropin-releasing hormone 26.63 CX3CR1 Chemokine (C-X3-C motif) receptor 1 13.64
NGFRAP1 Nerve growth factor receptor (TNFRSF16) 
associated protein 1
25.86 COTL1 Coactosin-like 1 (Dictyostelium) 13.4
SERPING1 Serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1, (angioedema, 
hereditary)
25.83 ADAM19 ADAM metallopeptidase domain 19 
(meltrin beta)
13.24
MAP7 Microtubule-associated protein 7 25.11 IL2RB IL-2 receptor beta chain 13
SOCS2 Suppressor of cytokine signaling 2 24.44 ITK IL2-inducible T-cell kinase 11.91
TSC22D1 TSC22 domain family, member 1 24.12 KLRC4 Killer cell lectin-like receptor subfamily 
C, member 4
11.36
H1F0 H1 histone family, member 0 22.71 CCL4 MIP-1 beta 11.22
RBPMS RNA binding protein with multiple splicing 22.67 CTSH Cathepsin H 11.18
CTDSPL CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase-like
22.64 EBI2 Epstein-Barr virus induced gene 2 
(lymphocyte-specific G protein-coupled 
receptor)
10.69
CDCA7 Cell division cycle associated 7 22.49 GIMAP4 GTPase, IMAP family member 4 10.28
CYTL1 Cytokine-like 1 20.9 POU2F2 POU domain, class 2, transcription factor 
2
10.22
FLT3 Fms-related tyrosine kinase 3 20.45 CXCR4 CXCR4 = CXC chemokine receptor 4 10.11
PRKAR2B Protein kinase, cAMP-dependent, 
regulatory, type II, beta
20.09 CYP4A11 Cytochrome P450, family 4, subfamily A, 
polypeptide 11
10.1
TRIM58 Tripartite motif-containing 58 19.18 LGALS3 Lectin, galactoside-binding, soluble, 3 
(galectin 3)
9.61
FSCN1 Fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus)
18.91 SNX27 Sorting nexin family member 27 9.44
C1orf150 Chromosome 1 open reading frame 150 18.83 TRIM26 Tripartite motif-containing 26 9.23
TRH Thyrotropin-releasing hormone 17.56 SNX27 Sorting nexin family member 27 9.05
KIT V-kit Hardy-Zuckerman 4 feline sarcoma 
viral oncogene homolog
17.27 CSPG2 Chondroitin sulfate proteoglycan 2 
(versican)
8.89
WASF1 WAS protein family, member 1 16.75 IL32 Interleukin 32 8.76
*The groups were compared using t-tests (p < 0.001).Journal of Translational Medicine 2008, 6:39 http://www.translational-medicine.com/content/6/1/39
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Measures in addition of CD34 and CD133 are needed to
more completely characterize HSCs.
Our results show that the global miRNA and cDNA
expression assessment can distinguish different types of
HSCs. Both types of global gene expression arrays were
able to distinguish the two types of HSCs that we studied
and both should be useful for potency testing of clinical
HPC components. miRNA and cDNA microarray assays
with several thousand probes usually require several days
to complete, but it would be possible to more rapidly ana-
lyze the expression of a smaller selected group of miRNA
or genes.
In conclusion, HSCs and PBLs have unique miRNA
expression profiles and many cancer-associated miRNA
are expressed by HSCs. miRNA and gene expression
microarrays maybe useful for assessing differences in
HSCs.
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